A 13% decline in the past year continues downward. Some of the decline might be explained by pandemic-related drop in healthcare utilization.
The opioid epidemic is hardly over, but Prime Therapeutics, the PBM for 23 Blues plans, is seeing notable declines in a number of measures of opioid prescribing among its claims.
In a review of it claims data from 16 million commercial members over the past year, Prime found a 13% decline in the number of members with an opioid claim and a similar reduction (12%) in members with a prescription for a high dose of opioids (90 morphine milligram equivalents or above).
Cathy Starner
“Obviously it is a good thing, we think, if there are fewer people getting opioids prescribed to them, because there are just a few instances when you actually need an opioid for pain control,” Cathy Starner, Pharm.D., health outcomes consultant senior principal, said in a recent interview with MHE.
Starner said the decline in opioid prescriptions be partly because of the pandemic-related decline in healthcare utilization, which was particularly steep during April and May of last year. But she also noted that the decline in opioid prescriptions among Prime’s claim goes back several years, so the recent decline is part of longer-term trend.
Prime has also seen a decline in its claims in the average days’ supply of opioids, from 16 to 15 days.
“Instead of you getting the seven-day supply day, when you are getting 50 tablets or whatever might be, you are getting 20 tablets for a three-day supply,” said Starner.
Prime, which is headquartered in Eagan, Minnesota, a Twin Cities suburb, has several programs designed to curb excessive and potentially harmful opioid prescribing, including utilization management at the point of sale. “If you are getting aprescription for the first tine and you don’t have any claims in your history, you probably don’t need a high dose or a large supply of an opioid,” Starner said.
Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.
Listen
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen